<p>Numerous researchers have explored the efficacy of the use of bisphosphonates, in particular alendronate and zoledronate, in bone graft integration. Mechanisms underlying the beneficial effects of bisphosphonates on bone graft integration have been previously investigated. Previous studies have demonstrated that both local and systemic applications of bisphosphonates in the integration of autogenous and allogenic bone grafts yield promising results in enhancing allograft and autograft outcomes. Several animal studies have revealed that low to moderate doses of local bisphosphonate optimize new bone formation with good mechanical properties. In addition, bisphosphonates in combination with certain growth factors, such as bone morphogenetic protein (BMP)-7, have synergistic effects on the integration of both autogenous and allogenic bone grafts. However, only some clinical parameters support these findings from in vivo studies, including increased bone volume and density in bone-grafted areas following the integration of bone grafts. Thus, the present review aims to summarize and discuss the effects of bisphosphonates and the mechanistic insights associated with the integration of autogenous and allogenic bone grafts. The contradictory findings between studies will also be presented and discussed in this review. While the promising benefits of bisphosphonates on bone grafts have been reported, further research is still needed to investigate optimal dosage. Larger clinical trials to assess the long-term outcomes of bisphosphonates are required before they can be widely adopted in orthopedic, dental, and maxillofacial bone grafting procedures.</p>